ZeroStack verkauft Phatebo für 2.15 Millionen Euro an New Horizon Pharma

Von Public Technologies
  • ZeroStack verkauft seine 100-Prozent-Beteiligung an Phatebo für 2.15 Millionen Euro an New Horizon Pharma.
  • Der Kaufvertrag wurde am 3. November 2026 geschlossen.
  • Der Vollzug steht unter dem Vorbehalt der deutschen Investitionsfreigabe sowie weiterer Abschlussbedingungen.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zerostack Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-005837), on November 09, 2026, and is solely responsible for the information contained therein.